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Abstract
Background: Adherence to Highly active antiretroviral therapy (HAART) is a major predictor of the success of HIV/
AIDS treatment. Good adherence to HAART is necessary to achieve the best virologic response, lower the risk of
drug resistance and reduce morbidity and mortality. This study therefore aimed to determine the prevalence and
determinants of adherence to HAART amongst PLHIV accessing treatment in a tertiary location in Cross River
State, Nigeria.
Methods: A cross-sectional study was conducted among patients on HAART attending the Presidential Emergency
plan for AIDS relief (PEPFAR) clinic of the University of Calabar Teaching Hospital between October–December 2011.
A total of 411 PLHIV visiting the study site during the study period were interviewed. PLHIV who met the inclusion
criteria were consecutively recruited into the study till the desired sample size was attained. Information was
obtained from participants using a semi-structured, pretested, interviewer administered questionnaire. Adherence
was measured via patients self report and were termed adherent if they took at least 95% of prescribed medication
in the previous week prior to the study. Data were summarized using proportions, and χ2 test was used to explore
associations between categorical variables. Predictors of adherence to HAART were determined by binary logistic
regression. Level of significance was set at p < 0.05.
Results: The mean age of PLHIV who accessed treatment was 35.7 ± 9.32 years. Females constituted 68.6% of all
participants. The self reported adherence rate based on a one week recall prior to the study was 59.9%. The major
reasons cited by respondents for skipping doses were operating a busy schedule, simply forgot medications, felt
depressed, and travelling out of town. On logistic regression analysis, perceived improved health status [OR 3.11; CI:
1.58-6.11], reduced pill load [OR 1.25; 95% CI: 0.46-2.72] and non-use of herbal remedies [OR 1.83; 95% CI: 1.22-2.72]
were the major predictors for adherence to HAART. However, payment for ART services significantly decreased the
likelihood of adherence to HAART. [OR 0.46; 95% CI: 0.25-0.87.].
Conclusions: The adherence rate reported in this study was quite low. Appropriate adherence enhancing
intervention strategies targeted at reducing pill load and ensuring an uninterrupted access to free services regimen
is strongly recommended.
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Background
The Human immunodeficiency virus (HIV) pandemic
continues to spread in the population making HIV infec-
tion one of the most important public health crises in the
world [1]. Globally, about 33.3 million persons were esti-
mated to be infected with HIV/AIDS in 2010, of these, 22.5
million (68%) are in sub Saharan Africa and about 3 million
alone in Nigeria. This makes it the country with the second
highest burden of HIV and AIDS in the world after South
Africa [1]. The current prevalence rate of HIV in Nigeria as
at 2010 based on the sentinel surveillance is 4.1%. Cross
River State were the study was conducted currently has the
9th highest prevalence (7.1%) in the country as at 2010 and
is found in the South-south geopolitical zone of Nigeria [2].
In the absence of a cure, antiretroviral therapy (ART) has
remained the only available option that offers the possibility
of dramatically reducing HIV/AIDS-related morbidity and
mortality, while improving the status of PLHIV. It has
proved effective in reducing viral load, improving immune
function, [3] and improving the quality of life of PLHIV
[3,4]. However, successful long-term treatment of HIV re-
quires strict adherence to the Highly Active Antiretroviral
Therapy (HAART) regimen [3,5,6]. This is especially
important in countries such as Nigeria where PLHIV
make up 10% of the global burden of HIV/AIDS [1]
and about 1.5 million require treatment [7]. Adherence
level of at least 95% and above has been considered ap-
propriate to achieve therapeutic success, [8-11] as this
maintains optimal viral suppression as demonstrated by
Paterson and colleagues [11-13]. Failure to observe
sustained desired adherence threshold has been associated
with dire consequences such as treatment failure, disease
progression and emergence of drug resistant HIV/IADS
strains [14,15].
With the realization of the central role played by ad-
herence in the success of HIV/AIDS treatment, several
studies conducted in various parts of the world including
reviews have reported non-adherence rates ranging from
50% to 80% in different contexts [9,10,16]. However, in
reality adherence rates are often lower than 95% [11]
and rates of adherence from previous studies conducted
in Nigeria have ranged from as low as 44% being adherent
[17] to more than 95% from different parts of Nigeria [18].
Most of the previous reports were carried out with fewer
PLHIV being on treatment restricted access to ARV drugs
unavailability and payment for ARV medications were
heavily subsidized.
With wide spread awareness of HIV/AIDS, expansion
of treatment and prevention programs that have increased
ART access to previously un-served and underserved popu-
lations in Nigeria coupled with provision of free ART ser-
vices, [19] there is a need for implementation of continuous
monitoring and evaluation mechanisms for adherence,
This is of great importance especially because the key
to the success of ART programmes and prevention of
treatment failures is hinged on consistently high adher-
ence levels. Scaling up of ARVs alone is definitely not
the answer when adherence inconsistencies are not
tackled. Therefore, the first step to solving this prob-
lem is to assess the determinants of adherence to
HAART which may differ across geopolitical zones of
the country with their unique characteristics of cul-
ture, religion, educational status and health seeking be-
haviours. The objectives of the present study were to
determine the prevalence of adherence to HAART and
identify factors associated with adherence.
Methods
The study was conducted at the President’s Emergency
plan for AIDS Relief (PEPFAR) clinic now the Specialist
treatment clinic of the University of Calabar Teaching
Hospital. The Hospital was selected as a centre for the
implementation of the President’s Emergency plan for
AIDS Relief (PEPFAR) by the United States Agency for
International Development (USAID) in June 2005. It has
since been responsible for the provision of care and sup-
port services for PLHIV as well as one of the major cen-
tres where PLHIV both in Cross River and other
neighbouring states receive anti retroviral therapy. The
patient population is about 4,000, of which more than
2,000 are on treatment. The clinic is run under three
units. The paediatric adult and the Prevention of Mater-
nal to Child transmission (PMTCT) clinics.
Study population
The study population comprised of 411 HIV positive
clients who were enrolled and had commenced HAART
in UCTH from October 2011- December 2011. They were
made of 129 males and 282 females. Participants were
consecutively recruited over the study period till the de-
sired sample size was attained. All PLHIV on HAART
were eligible to participate except those that satisfied the
exclusion criteria. These criteria included PLHIV below
18 years of age, who were attending the clinic but had not
commenced HAART, terminally ill patients and pregnant
women. The inclusion criteria adopted for the study in-
cluded consenting out patients diagnosed and confirmed
to be HIV positive, at least 18 years of age and had been
on HAART for 3 months.
Study design
A cross-sectional analytical study aimed at documenting
the level of adherence among PLHIV on HAART was
conducted between October 2011- December 2011.
Data collection instrument
This consisted of an interviewer administered semi-struc-
tured questionnaire which was divided into sections to
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collect relevant information on socio-demographic data,
medical profile including treatment experiences at health
facility of respondents. Adherence to HAART in the
previous seven days of the interview was measured by
self-report. The questions were adopted from The Brief
Medication Questionnaire self-report tool for screening
adherence and barriers to adherence [20]. The degree
of adherence from patient self-reporting was estimated
using the following formula: [21]
% Adherence over last 7 days
¼ #doses should have taken‐#missed doses 100%
#Doses should have taken
Then, the percentage of adherence to the antiretroviral
was estimated by the average of adherence to the drugs.
For the purpose of this study a score of 95% and above
represented good adherence and less than 95% was rated
as having poor/suboptimal adherence.
Table 1 The Socio-demographic characteristics of study




















Post secondary 163 39.7
Occupation
Professional/managerial/technical 126 30.7
Skilled manual 41 10.0
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Table 2 Medication/treatment variables including

















Presence of opportunistic infection
Yes 32 7.8
No 379 92.2
Paid for ART services
Yes 49 11.9
No 362 88.1
Perceived health status as improved
since commencement of HAART
Improved 386 93.9
No improvement 25 6.1
Perceived health rating
Excellent 39 9.5
Very good 253 61.6
Good 92 22.4
Fair/poor 27 6.6
Transportation cost to Health facility
<N1000 275 66.9
≥N1000 136 33.1
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Data analysis
Data were analyzed using SPSS for windows version 19.0.
Descriptive and inferential statistical tests were employed.
These included bivariate (chi-square) and multivariate
(logistic regression) analysis to determine correlates or
predictors of adherence. Descriptive statistics (frequencies,
proportions, means and standard deviation to summarize
variables while Inferential statistics (chi square Test) was
used to test the significance of association between cat-
egorical variables and level of significance was set at 5%.
Logistic regression analysis was used to identify the pre-
dictors of adherence to HAART in the study population.
Variables entered into the logistic model were those which
had earlier been significantly associated on bivariate analysis
at 10% significance derived. Predictors were determined at
5% significance.
Ethical clearance and consent
The ethical Committee of the University of Calabar
Teaching Hospital reviewed and approved the study
procedures and data collection instruments.
Results
Four hundred and eleven eligible respondents receiving
HAART at the PEPFAR clinic UCTH were studied. The
mean age of respondents was 35.7 ± 9.3 years. The largest
proportion of the PLHIV 171 (41.6%) were in the age
group 25-34 years, followed by 136 (33.1%) in the 35 to 44
age group. The majority of those interviewed were female;
68.6% and currently married 51.8%. More than a third
39.7% had attained at least secondary education and
38.4% were of the skilled non manual occupational
group. Also majority 85.9% resided within the state and
67.4% earned less than the minimum wage in Nigeria
(<N19,000) monthly which is equivalent to $118.75. Al-
most all (99.8%) respondents interviewed were Christians
(Table 1). The Medical profile of respondents interviewed
(Table 2) revealed that more, 183 (44.5%) had been on
HAART for more than 24 months. The median duration
on HAART was 24 months (range 3–192 months). More
than half of the study population 226 (55%) had encoun-
tered side effects since the commencement of HAART and
majority 273 (66.4%) were not using any form of herbal
treatment alongside their antiretroviral medications.
Furthermore, a little over two-thirds of the respondents
282 (68.6%) were on at least 2 pills per day and a vast
majority 386 (93.9%) perceived their health status as
improved since their commencement on HAART. A
few respondents 49 (11.9%) of the study population
reported paying for services at the treatment site.
Prevalence of adherence to HAART in the study popula-
tion showed that more than half (59.9%) of the respondents’
attained 95% adherence to prescribed HAART regimen.
The main reasons cited for missing or skipping doses
among respondents who missed their medications included
being busy (43.8%), simply forgetting (31.1%), depression
(20%), frequent travelling (14.8%) and inconvenient timing
for medications schedule (12.7%). This is represented
in Figure 1.
Factors associated with adherence on bivariate analysis
(Tables 3 and 4) were; Being resident outside Cross river
state, 42 (72.4%) was significantly more likely to adhere to
Figure 1 Reasons for missing/skipping medications.
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HAART compared with 204 (57.8%) being resident
within the state (p < 0.05). Similarly other significant
correlates of adherence included obtaining free ART
services, perceived health status as excellent/good and
paid more than N1000 on transportation to the health
care facility (p < 0.05) (Table 4). The predictors of adher-
ence to HAART amongst PLHIV accessing treatment in
PEPFAR clinic UCTH were non use of herbal remedies,
obtaining free ART services, perceived improvement in
health status, and reduced pill load. Participants not
using herbal remedies were more likely to adhere to
their prescribed doses compared with those using herbal
remedies. Similarly obtaining free ART services, taking
not more than two pills per day, and a perceived im-
provement in health following the commencement of
HAART than those who paid for ART services, took
more than 2 pills per day, and who reported their per-
ceived health status as not improved. This is presented
in Table 5.
Discussion
The present study aimed to contribute towards addressing
gap in knowledge regarding the prevalence and factors as-
sociated with treatment adherence among a representative
sample of PLHIV accessing treatment site in Cross River
State Nigeria.
The self reported adherence reported in the present
study was 59.9%. This finding was comparable with other
studies done in Nigeria and other African setting, [21-23]
but slightly higher than earlier reports by Ilyasu and
colleagues in Kano (Northern Nigeria), [18] Nwauche
and colleagues (Southern Nigeria) and a study done in
Kenya, who reported adherence levels of 54.5%. 49.2%
and 43.2% respectively. However adherence level reported
in this study was lower than seen in other studies
[22,24-26]. Our current findings showed that about
two fifths of patients interviewed were non adherent
both in terms of dose adherence and timing. Emphasis
should therefore be placed on adherence to HAART
Table 3 Distribution of socio-demographic characteristics, of the study participants by their ART adherence pattern
Characteristics Good adherence Poor adherence Significance
N = 246 (N = 165)
Frequency (%) Frequency (%)
Age (years)
≤35 137(58.3) 98(41.7) p = 0.46
>35 109(61.9) 67(38.1) x2 = 0.55
Sex
Male 78(60.5) 51(39.5) p = 0.864
Female 168(59.6) 114(40.4) x2 = 0.02
Marital status
Married 133(62.4) 80(37.6) p = 0.27
Not married 113(57.1) 85(42.9) x2 = 1.23
Level of Education
None 11(57.9) 8(42.1)
Primary 36(54.5) 30(45.5) p= 0.47
Secondary 94(57.7) 69(42.3) x2 = 2.54
Tertiary 105(64.4) 58(35.6)
Residence
Within Cross river 204(57.8) 149(42.2) p = 0.035
Outside Cross river Herba 42(72.4) 16(27.6) x2 = 4.43
Occupation
Professional managerial/Technical 80(63.5) 46(36.5)
Skilled manual 23(56.1) 18(43.9) p= 0.74
Skilled non manual 94(59.5) 64(40.5) x2 = 1.24
Unskilled/unemployed/retired 49(57.0) 37(43.0)
Average monthly income
≤ N19,000 163(58.8) 114(41.2) p=0.55
>N19,000 83(61.9) 51(38.1) x2 = 0.36
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especially during counselling sessions as this is re-
quired for optimal clinical response and complete viral
suppression.
The major reasons cited by participants for missing
doses included; operating a busy schedule and simply
forgetting medications. These two reasons though related
to one another have been cited by several studies as the
main risk factors for suboptimal adherence [21,23,27-29].
Another important reason given by respondents for
skipping or missing medications which is note worthy
was feeling depressed. Approximately a fifth of the study
population indicated feeling depressed as a reason for
poor adherence to medications. This was similar to
findings conducted in USA in 2010 where patients with
symptoms of depression had higher rates of suboptimal
adherence [30]. Issues bothering around stigma and dis-
crimination, personality traits, fear of being discovered,
lack of social support, and poorer health outcomes may
contribute strongly to emotional non-adjustment to
HIV/AIDS, depression and loss of interest in ones treat-
ment. This would ultimately result in poor adherence to
medications amongst PLHIV.
Most socio-demographic characteristics such as age, sex,
marital status, educational attainment did not significantly
affect adherence levels amongst our study population. This
corroborates the findings of some authors [17,28,31,32]
but refutes the findings of others were certain socio-
demographic variables were associated with being adherent
to HAART [24,33].
Medication adherence was found to be significantly
associated with non use of Traditional herbal medicines.
The effect of the use of herbal remedies in addition to
HAART was noted in this study. Non herbal use was
demonstrated as a significant predictor of adherence in
Table 4 Distribution of Medical profile/treatment experiences of the study participants by their ART adherence pattern
Characteristics Good adherence
N = 246 Frequency (%)
Poor adherence
(N = 165) Frequency (%)
Significance
Use of Herbal remedies
Yes 74(53.6) 64(46.4) p = 0.07
No 172(63.0) 101(37.0) x2 = 3.36
Number of pills/day
≤2 161(57.1) 121(42.9) p = 0.091
>2 85(65.9) 44(34.1) x2 = 2.85
Opportunistic infections
Yes 18(56.2) 14(43.8) p = 0.665
No 228(60.2) 151(39.8) x2 = 1.88
Paid for ART services
Yes 21(42.9) 28(57.1) p = 0.01
No 225(62.5) 137(37.8) x2 = 6.69
Rating of Perceived Health
Excellent/good 238(62.0) 152(39.4) p = 0.01
Fair/poor 8(29.6) 19(70.4) x2 = 10.1
Perceived health status
Improving 234(60.6) 152(39.4) p = 0.21
Not improving 12(48.0) 13(52.0) x2 = 1.56
Encountered side effects
Yes 126(55.8) 100(44.2) p = 0.061
No 120(64.9) 65(35.1) x2 = 3.52
Cost of transportation to health centre
<N1000 ($ 6.25) 154(56.0) 121(44.0) p = 0.023
>N1000 ($ 6.25) 92(67.6) 44(32.4) x2 = 5.14
Duration on HAART(months)
<24 116(60.1) 77(39.9) p = 0.864
≥24 130(59.6) 88(40.4) x2 = 0.029
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this study. This finding is in agreement with a study
conducted in Ilorin, (south western Nigeria) were the use
of herbal medicines was a major risk factor for non adher-
ence [34] and a study done in South Africa by Peltzer et al.
which demonstrated non use of herbal remedies as a major
facilitator of adherence [26]. The reason respondents may
consider using herbal remedies could be attributable to the
fact that some patients may gradually be losing faith in their
anti-retrovirals which most are aware does not provide a
cure and are opting for herbal remedies. Secondly, the pro-
liferation of alternative healers and a claim on the media by
traditional medicine practitioners of an instant cure for
HIV infection may cause some to abandon their treatment.
Pill burden also significantly affected adherence in
the present study. Respondents on more than two pills
per day were less likely to adhere to their treatment
compared to those on at least two pills per day. This
finding was also identified as a significant predictor of
adherence in a study done by Falang and colleagues in
Jos [25] and Sow et al. in Senegal [35] where pill bur-
den was reported to have a strong impact on adher-
ence. Similarly, in India Cauldbeck et al. demonstrated
that patients who attained 100% adherence took fewer
pills [36]. This could be attributable to the fact that
these patients probably because of their busy schedules
may have been unable to incorporate their drugs schedule
into their daily schedule or may be developing pill fatigue.
Reducing pill load as well as dosing schedules to once or
twice daily has been found to be associated with better
adherence [25].
Self reported improved health status was significantly
associated with adherence amongst our study population.
The odds of adherence among those who rated their health
status as improved was three times compared to those who
perceived their health as not improved. This study was in
agreement with another study [37] where staying healthy
was a key motivator of adherence to treatment. In contrast
to our findings, Olowookere and colleagues in south
western Nigeria reported that feeling good/healthy,
were risk factors for non-adherence. They further
reported that most patients tend to abandon treatment
once there was an improvement in their health [21,23].
Obtaining free treatment at ART clinics was a signifi-
cant predictor of adherence to treatment. Respondents
who didn’t pay for obtaining ART services were two
times better adherers compared to those who paid for
services. This was in keeping with studies done in the
south western part of Nigeria, [33] and another study
done in Botswana when cost were removed as a barrier,
adherence was predicted to increase from 54% to 74%
[11]. Financial constraints among respondents were a
major deterrent to adherence as observed in this study.
Although drugs were given free of charge in most health
facilities offering ART services, patients are still required
to pay some user fees at health facility e.g. opening of
folders, certain laboratory investigations and treatment of
opportunistic infections. In addition there are some indir-
ect costs these patients bear e.g. cost of transportation to
the health care facility. Non-payment of services at every
HAART clinics should be enforced and providing free
treatment for opportunistic infections will also go a long
way in improving adherence.
Certain limitations of this study should be recognized.
The cross-sectional nature of the survey did not allow
for inferences to be drawn as to causal relationship among
variables. The use of self report medication adherence to
assess medication adherence was a limitation in this study
since participants had to recall their medication adherence
in the previous week. Concerted efforts were made to
reduce recall bias by limiting recall of medication to
7 days prior to the study which was in itself a limitation
because of the possibility that subjects would either
over- or underestimated their adherence to HAART.
This was further worsened by the inability to corroborate
patient self- report of adherence with viral loads and CD4
responses because of financial and logistic constraints
of frequent laboratory monitoring. This was because
restricted access to patient’s folders.







Use of herbal remedies
No 1.83 1.22- 2.72 0.003
Yes 1
Paid for ART services
Yes 0.46 0.25- 0.87 0.017
No 1
Pill number




Improving 3.11 1.58-6.11 0.001
Not improving 1
Residence
Outside Cross river 0.76 0.40-1.47 0.42
Within Cross river 1
Encountered side effects
Yes 0.92 0.65-1.29. 0.61
No 1
Transportation costs
<N1000 ($ 6.25) 0.76 0.50-1.16 0.20
≥N1000 ($ 6.25) 1
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Conclusion
This study showed that medication adherence rate was
low among PLHIV accessing treatment in UCTH Calabar,
Nigeria. It is also obvious that there are barriers to adher-
ence therefore efforts should be targeted and assessed for
each patient so that appropriate adherence enhancing inter-
ventions can be undertaken. The authors therefore recom-
mend that non-payment of services at every ART clinics
and provision of free treatment should also include oppor-
tunistic infections and required investigations. This will go
a long way in improving adherence. Also the focus during
counselling sessions should discourage the use of trad-
itional herbal remedies alongside HAART which has been
seen to affect adherence in the present study. In addition,
curtailing the activities of Alternative medical practitioners
in the country claiming to have found a cure for HIV/AIDS
would be of immense help. Pharmaceutical companies in-
volved in manufacture of ARVs should ensure that all
recommended ARV regimens should consist of not more
than two pills per day.
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